Zoetis Inc Class A (ZTS)

Industry Drug Manufacturers - Specialty & Generic

This stock can be held in an Investment ISA and an Investment Account

Sell

$87.00

Buy

$89.01

arrow-up$6.21 (+7.48%)

Prices updated at 05 Nov 2026, 00:59 EST

Prices minimum 15 mins delay

Prices in USD

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 30% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 70% from companion animal (dog ...

S&P 500

1.58%

NYSE

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

our Investment Fees and Charges.

Income statement

Year chevron-l-regular chevron-r-regular	2024	2025
	9,256m	9,467m
	6,537m	6,801m
	3,392m	3,597m
	36.65	38.00
	2,486m	2,673m
	3,855m	4,069m
Sales, General and administrative	2,318m	2,378m
Interest expenses	225m	222m
Provision for income taxes	637m	687m
Operating expenses	3,145m	3,204m
Income before taxes	3,133m	3,360m
Net income available to common shareholders	2,486m	2,673m
	5.47	6.03
Net interest income	-119m	-129m
Advertising and promotion	-	-
Net investment income, net	-	-
Realised capital gains (losses), net	-	-
Total benefits, claims and expenses	-	-
Earnings per share (diluted)	5.47	6.02
Free cash flow per share	5.0493	5.0115
Book value/share	11.6707	12.7033
Debt equity ratio	1.130818	2.773341

Balance sheet

Year chevron-l-regular chevron-r-regular	2024	2025
Current assets	5,986m	6,768m
Current liabilities	3,412m	2,235m
Total capital	9,990m	12,373m
Total debt	6,744m	9,238m
Total equity	4,770m	3,331m
Total non current liabilities	-	-
Loans	5,220m	9,042m
Total assets	14,237m	15,467m
Total liabilities	-	-
Cash and cash equivalents	1,985m	2,310m
Common stock	448m	425m

Cash flow

Year chevron-l-regular chevron-r-regular	2024	2025
Cash at beginning of period	2,041m	1,987m
Cash dividends paid	-786m	-889m
	2,298m	2,283m
Investments (gains) losses	-315m	-748m
	1,987m	2,312m
Net income	-	-
	2,953m	2,904m
	-655m	-621m

The figures shown in the tables are quoted in the currency of the stock selected.

Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser.

© Copyright 2026 Morningstar. All rights reserved. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.

The ESG-related information, methodologies, tools, ratings, data and opinions contained or reflected herein are not directed to or intended for use or distribution to India-based clients or users and their distribution to Indian resident individuals or entities is not permitted, and Morningstar accepts no responsibility or liability whatsoever for the actions of third parties in this respect.